Clinical Trials · NCT04934722
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 186
- Start date
- May 2021
- Locations
- 24 sites, China
- Primary endpoint
- Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)